Effectiveness of Integrative Intervention Strategies for Binge Eating in Patients With Overweight or Obesity: A Multidisciplinary Approach
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Binge Eating
- Sponsor
- G. d'Annunzio University
- Enrollment
- 100
- Primary Endpoint
- objective BE episodes (OBEs)
- Status
- Not Yet Recruiting
- Last Updated
- last year
Overview
Brief Summary
The main goal of the clinical trial is to compare the short- and long-term outcomes of three 12-week interventions among outpatients with overweight/obesity and binge eating (BE):
- treatment-as-usual for weight loss (TAU);
- combined TAU and guided self-help for improving eating behaviors (TAU+GSH);
- combined TAU, GSH, and biofeedback (TAU+GSH+BF). The primary outcomes will be self-reported reduction of days with objective BE episodes (OBEs).
The secondary outcomes will be impulsivity, emotion dysregulation, interoceptive awareness, distress, physiological correlates of arousal (skin conductance and heart rate variability), and inflammatory biomarkers.
The TAU+GSH arm is expected to be comparable to the TAU+GSH+BF arm in reducing the number of days with OBEs but is expected to be significantly less effective in improving secondary outcomes (impulsivity, emotional dysregulation, interoceptive awareness, distress, physiological inflammatory markers). The TAU arm is expected to show significant inferiority regarding the primary and secondary outcomes and cost-effectiveness compared to the TAU+GSH and TAU+GSH+BF conditions.
Investigators
CHIARA CONTI
Associate professor
G. d'Annunzio University
Eligibility Criteria
Inclusion Criteria
- •(1) age 18-65 years; (2) BMI≥25 kg/m2; (3) ability to read and write in Italian; (4) Binge Eating Disorder (BED) or subthreshold BED status.
Exclusion Criteria
- •(1) current treatment for BE with a registered psychologist; (2) severe psychiatric disorders; (4) cognitive impairment; (5) pregnancy; (6) severe medical comorbidity.
Outcomes
Primary Outcomes
objective BE episodes (OBEs)
Time Frame: 12-week follow-up-1 4-month follow-up-2 (after the end-of-treatment)
The primary outcomes will be self-reported reduction of days with objective BE episodes (OBEs)
Secondary Outcomes
- physiological correlates of arousal((T0) baseline; (T1)12-week follow-up-1; (T2) 4-month follow-up-2 (after the end-of-treatment))
- psychological variables((T0) baseline; (T1)12-week follow-up-1; (T2) 4-month follow-up-2 (after the end-of-treatment))
- inflammatory biomarkers((T0) baseline; (T1)12-week follow-up-1; (T2) 4-month follow-up-2 (after the end-of-treatment))